HEALTH CARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH HIV-POSITIVE PATIENTS WITH COMORBIDITY VERSUS HIV-NEGATIVE PATIENTS WITH COMORBIDITY

Author(s)

Lachaine J1, Baribeau V2, Lorgeoux R3, Tossonian H3
1University of Montreal, Montreal, QC, Canada, 2PeriPharm Inc., Montreal, QC, Canada, 3Gilead Sciences Canada, Mississauga, ON, Canada

OBJECTIVES: The success of antiretroviral therapy (ART) has led to human immunodeficiency virus (HIV) being considered a treatable chronic condition. However, the need for life-long therapy in HIV-positive patients presents a number of challenges including long-term renal, cardiovascular (CV) and bone toxicities. The study objective was to evaluate the impact of HIV on health care resource utilization and costs among patients with comorbidities, using the Quebec public drug plan database (RAMQ) METHODS: HIV-positive patients who had received ART for at least 6 months from January 2006 to June 2012 were selected and categorized in 4 groups: 1) patients with CV, bone or renal comorbidity, 2) patients with CV comorbidity, 3) patients with bone comorbidity and 4) patients with renal comorbidity. Three controls of HIV-negative patients with the same comorbidities were matched for age groups and gender to each HIV-positive case. Comorbidity date was defined as the date of the first medication, diagnosis or medical procedure related to comorbidities. Health care resource utilization and costs were measured in the 2 years following comorbidity date.

RESULTS: A total of 1,983 HIV-positive patients with comorbidity were identified, in which 1,498 had CV comorbidity, 915 had bone comorbidity and 191 had renal comorbidity. The mean total health care cost per year was higher in HIV-positive than in HIV-negative patients with comorbidity (CAN$22,037;SD=16,935 vs. CAN$3,620;SD=7,418, p<0.01). For patients with CV and bone comorbidity, similar results were obtained. For patients with renal comorbidity, the mean total health care cost per year was higher for HIV-positive than for HIV-negative patients (CAN$29,759;SD=24,827 vs. CAN$9,193;SD=17,659, p<0.01) and costs in both groups were higher than groups with other comorbidities.

CONCLUSIONS: HIV-positive patients with renal, bone or CV comorbidities had increased health care costs when compared to HIV-negative patients with the same comorbidities. Renal comorbidity had the highest health care costs.

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PIN69

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×